WO2013076702A3 - Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs) - Google Patents

Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs) Download PDF

Info

Publication number
WO2013076702A3
WO2013076702A3 PCT/IB2012/056688 IB2012056688W WO2013076702A3 WO 2013076702 A3 WO2013076702 A3 WO 2013076702A3 IB 2012056688 W IB2012056688 W IB 2012056688W WO 2013076702 A3 WO2013076702 A3 WO 2013076702A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
monoclonal antibodies
hybridoma
secreted
relates
Prior art date
Application number
PCT/IB2012/056688
Other languages
English (en)
French (fr)
Other versions
WO2013076702A2 (es
Inventor
Alexis Mikes Kalergis Parra
Susan Marcela Bueno Ramirez
Jorge Eugenio MORA ALARCON
Roberto Sebastián GÓMEZ JOHNSON
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Priority to MX2014006248A priority Critical patent/MX349235B/es
Priority to EP12851478.3A priority patent/EP2784088B1/en
Priority to BR112014012608-9A priority patent/BR112014012608B1/pt
Priority to IN4823CHN2014 priority patent/IN2014CN04823A/en
Priority to ES12851478.3T priority patent/ES2657619T3/es
Priority to CN201280062779.9A priority patent/CN103998465B/zh
Priority to CA2856258A priority patent/CA2856258C/en
Priority to US14/360,219 priority patent/US9273122B2/en
Publication of WO2013076702A2 publication Critical patent/WO2013076702A2/es
Publication of WO2013076702A3 publication Critical patent/WO2013076702A3/es
Priority to ZA2014/03564A priority patent/ZA201403564B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al uso de anticuerpos monoclonales específicos para el virus respiratorio sincitial (VRS). Concretamente, a un anticuerpo monoclonal IgG2A secretado por la línea celular de hibridoma 8A4/G9 dirigido específicamente para el antígeno viral M2-1, el cual está asociado a la nucleocápside del virus. Los anticuerpos pueden ser utilizados para ensayos de detección y/o determinación de infección por VRS. También se proporciona un método para prevención y tratamiento de la infección causada por VRS, que comprende la administración de una composición que comprende los anticuerpos monoclonales secretados por el hibridoma 8A4/G9. Por último, la invención también proporciona métodos de diagnóstico y detección de antígenos virales de VRS en muestras biológicas, en la cual se utilicen los anticuerpos monoclonales producidos y secretados por células del hibridoma 8A4/G9.
PCT/IB2012/056688 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs) WO2013076702A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2014006248A MX349235B (es) 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs).
EP12851478.3A EP2784088B1 (en) 2011-11-25 2012-11-23 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv)
BR112014012608-9A BR112014012608B1 (pt) 2011-11-25 2012-11-23 Anticorpos monoclonais específicos para o antígeno m2-1 do vírus respiratório sincicial (vrs), conjunto de sequências nucleotídicas e método e kit de diagnóstico do rsv
IN4823CHN2014 IN2014CN04823A (es) 2011-11-25 2012-11-23
ES12851478.3T ES2657619T3 (es) 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno M2-1 del virus respiratorio sincicial (VRS)
CN201280062779.9A CN103998465B (zh) 2011-11-25 2012-11-23 对于呼吸道合胞病毒(rsv)的m2‑1抗原而言特异的单克隆抗体
CA2856258A CA2856258C (en) 2011-11-25 2012-11-23 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv)
US14/360,219 US9273122B2 (en) 2011-11-25 2012-11-23 Monoclonal antibodies specific for the M2-1 antigen of respiratory syncytial virus (RSV)
ZA2014/03564A ZA201403564B (en) 2011-11-25 2014-05-16 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2011003002A CL2011003002A1 (es) 2011-11-25 2011-11-25 Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
CL3002-2011 2011-11-25

Publications (2)

Publication Number Publication Date
WO2013076702A2 WO2013076702A2 (es) 2013-05-30
WO2013076702A3 true WO2013076702A3 (es) 2013-07-25

Family

ID=51205767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/056688 WO2013076702A2 (es) 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs)

Country Status (13)

Country Link
US (1) US9273122B2 (es)
EP (1) EP2784088B1 (es)
CN (1) CN103998465B (es)
AR (1) AR088987A1 (es)
CA (1) CA2856258C (es)
CL (1) CL2011003002A1 (es)
ES (1) ES2657619T3 (es)
IN (1) IN2014CN04823A (es)
MX (1) MX349235B (es)
PE (1) PE20141683A1 (es)
PT (1) PT2784088T (es)
WO (1) WO2013076702A2 (es)
ZA (1) ZA201403564B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014003373A1 (es) * 2014-12-11 2015-04-10 Univ Pontificia Catolica Chile Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.
JP6270781B2 (ja) * 2015-06-30 2018-01-31 田中貴金属工業株式会社 クロマト分析装置およびクロマト分析方法
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CA3111336A1 (en) * 2018-09-03 2020-03-12 Pontificia Universidad Catolica De Chile Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
CN115838419B (zh) * 2022-09-27 2023-06-30 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用
WO2024120517A1 (zh) * 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5762905A (en) * 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO2002102975A2 (en) * 2001-06-15 2002-12-27 C3 Scientific Corporation Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
WO2009088159A1 (en) * 2008-01-08 2009-07-16 Aprogen Inc. Antibodies to respiratory syncytial virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050646A1 (en) * 1999-02-26 2000-08-31 The Uab Research Foundation Methods of screening for antiviral compounds
EP1340086B1 (en) 2000-10-17 2008-07-30 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
EP1572108A4 (en) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
CN101130765B (zh) 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762905A (en) * 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
WO2002102975A2 (en) * 2001-06-15 2002-12-27 C3 Scientific Corporation Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
WO2009088159A1 (en) * 2008-01-08 2009-07-16 Aprogen Inc. Antibodies to respiratory syncytial virus

Also Published As

Publication number Publication date
PT2784088T (pt) 2018-01-31
ZA201403564B (en) 2015-08-26
US20140348858A1 (en) 2014-11-27
BR112014012608A2 (pt) 2020-10-27
CA2856258A1 (en) 2013-05-30
CL2011003002A1 (es) 2012-05-25
US9273122B2 (en) 2016-03-01
CN103998465A (zh) 2014-08-20
EP2784088B1 (en) 2017-10-25
CA2856258C (en) 2018-05-01
WO2013076702A2 (es) 2013-05-30
MX349235B (es) 2017-07-19
CN103998465B (zh) 2017-02-22
AR088987A1 (es) 2014-07-23
EP2784088A2 (en) 2014-10-01
MX2014006248A (es) 2015-03-03
EP2784088A4 (en) 2015-05-13
ES2657619T3 (es) 2018-03-06
PE20141683A1 (es) 2014-11-28
IN2014CN04823A (es) 2015-09-18

Similar Documents

Publication Publication Date Title
WO2013076702A3 (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs)
Eisenberg et al. Rituximab-treated patients have a poor response to influenza vaccination
US10125188B2 (en) Human antibodies to respiratory syncytial virus F protein and methods of use thereof
US11339206B2 (en) Compositions and methods for the treatment of immunodeficiency
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
RU2010120879A (ru) Антитела против g-белка распираторно-синцитиального вируса (rsv)
Caidi et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice
Hong et al. Antibody-secreting cells with a phenotype of Ki-67low, CD138high, CD31high, and CD38high secrete nonspecific IgM during primary hepatitis A virus infection
WO2013035345A3 (en) Dengue-virus serotype neutralizing antibodies
Su et al. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
Wang et al. Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
Launay et al. Factors associated with humoral immune response to pandemic A/H1N1 (v) 2009 influenza vaccine in cystic fibrosis
Schepens et al. IgG3 snitcher of RSV infections in the very young
Esmat et al. Immunoglobulin A response to SARS-CoV-2 infection and immunity
EP3848389A4 (en) SPECIFIC MONOCLONAL ANTIBODY AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HSRV) N ANTIGEN, USEFUL FOR INFECTION TREATMENT, DETECTION AND DIAGNOSIS
Malik et al. Respiratory Syncytial Virus Infection: Treatments and Clinical Management. Vaccines 2023, 11, 491
Duffy The Shivering Trials: A Novel Vaccine Strategy And Analysis Of Serologic Durability In Patients With Plasma Cell Dyscrasias
Acton Advances in Immunization Research and Treatment: 2013 Edition
AR106471A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2856258

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2012851478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 000728-2014

Country of ref document: PE

Ref document number: 2012851478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/006248

Country of ref document: MX

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12851478

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14360219

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014012608

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014012608

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140523